Ultomiris was originally approved in 2018 and is also indicated to treat adults with PNH and adult and pediatric patients with atypical hemolytic uremic syndrome.

When did Ultomiris launch?

Since its initial approval in 2018, ULTOMIRIS has quickly become the standard of care in the U.S. for the treatment of adults with PNH.

What is the difference between Soliris and Ultomiris?

Although they are similar in many respects, a key difference between the two medications is that Ultomiris is not cleared from the body as quickly as Soliris, requiring less frequent infusions.